New Advances and Challenges in Metabolic and Bariatric Surgery

Dear Colleagues,

It is with great pleasure and enthusiasm that I welcome you to this special edition of Journal of Personalized Medicine dedicated to the “New Advances and Challenges in Metabolic and Bariatric Surgery”. Obesity, an ever-growing global health concern, continues to demand innovative solutions, both surgical and pharmaceutical, to alleviate its profound impact on public health and individual well-being. This issue will provide a comprehensive overview of the latest developments in this field, with a particular focus on the expansion of indications for metabolic and bariatric surgery (MBS), novel single anastomosis bariatric procedures, transit bipartition surgeries grounded in incretin and anti-incretin theory, and emerging pharmaceutical interventions for obesity management.

Alarming Trends and Expanded Indications

The rising prevalence of obesity-related comorbidities such as type 2 diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease has spurred a paradigm shift in the application of bariatric surgery. Recent research has demonstrated the benefits of MBS in patients with lower BMI thresholds, emphasizing the role of surgery as a preventive measure and not just a treatment for severe obesity.

Incretins, Anti-Incretins, Transit Bipartition and Single Anastomosis Procedures

In this Special Issue, we delve into the cutting-edge field of MBS, exploring the latest advancements in transit bipartition and single anastomosis procedures rooted in the incretin and anti-incretin theory. These innovative surgeries, such as Single Anastomosis Sleeve Ileal (SASI) Bypass, harness the power of gut hormones to regulate glucose metabolism, appetite, and energy expenditure.  An essential component of these new procedures is intestinal bipartition, where the intestine is partitioned into two segments, each with distinct functions. This innovative approach plays a pivotal role in modulating incretin and anti-incretin responses, contributing to improved metabolic outcomes. We will examine the scientific underpinnings of these procedures and their clinical outcomes, shedding light on their potential to redefine the landscape of MBS.

Pharmaceutical Breakthroughs

Beyond surgical interventions, the realm of pharmacotherapy for obesity management is undergoing a renaissance. This issue will provide insights into the latest generation of anti-obesity medications, including incretin mimetics, leptin analogs, and selective serotonin receptor agonists. These pharmacological agents hold promise in addressing obesity with greater precision, potentially reducing the need for surgery in certain cases, or as a neo-adjuvant treatment and a bridge for surgery.

In conclusion, the field of MBS stands at the forefront of medical innovation, offering new hope to individuals struggling with obesity and its associated metabolic disorders. As guest editor, I am excited to present to you a collection of articles that encapsulate the diverse facets of this evolving field, from expanded indications to the frontiers of surgical techniques and pharmaceutical interventions. With the ever-increasing challenges posed by the obesity epidemic, it is our hope that this special edition of Journal of Personalized Medicine will inspire further research, collaboration, and innovation in the pursuit of effective and holistic solutions for obesity and its metabolic consequences.

Sincerely,

Dr. Hugo Santos-Sousa
Dr. Jorge Pedro Martins Nogueiro
Dr. André Costa-Pinho
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.